NASDAQ · ELOX
Eloxx Pharmaceuticals, Inc.
$13.45+$0.27 (+2.05%)
Eloxx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.52% below the high.
Loading market information…
OTC · NEXI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
NexImmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
NexImmune, Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$13.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow NexImmune, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$16.25-12.07% vs estimate |
| $0.00 |
| Q3 2022 | Nov 14, 2022 | -$15.00+9.09% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.45+$0.27 (+2.05%)
Eloxx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.52% below the high.
$0.05$0.00 (0.0%)
Micron Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.2% below the high.
$0.00$0.00 (0.0%)
Nutrition Management Services Company’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.00$0.00 (0.0%)
Biocept, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
$0.00$0.00 (0.0%)
Verde Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Nabriva Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Ormand Industries Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Biostar Pharmaceuticals, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
